Elicio Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview
25/03/2025 12:32
Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to show no change in quarterly revenue when it reports results on March 27 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Elicio Therapeutics Inc is for a loss of 87 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Elicio Therapeutics Inc is $11.00, above its last closing price of $8.50. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Sep. 30 2024 | -0.71 | -0.73 | -1.39 | Missed | -90.4 |
| Jun. 30 2024 | -0.96 | -0.96 | -0.64 | Beat | 33.3 |
| Mar. 31 2024 | -1.08 | -1.09 | -1.15 | Missed | -5.5 |
| Dec. 31 2023 | -1.03 | -0.78 | -1.75 | Missed | -122.9 |
| Sep. 30 2023 | -0.80 | -0.80 | -1.27 | Missed | -58.7 |
| -2.44 | | ||||
| -1.50 | |||||
| Dec. 31 2022 | -2.10 | -2.10 | Met | 0 |
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)